Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

L Rosiñol, M Beksac, E Zamagni… - British journal of …, 2021 - Wiley Online Library
In this review, two types of soft‐tissue involvement in multiple myeloma are defined:(i)
extramedullary (EMD) with haematogenous spread involving only soft tissues and (ii) …

Development of CAR-T cell therapies for multiple myeloma

N Gagelmann, K Riecken, C Wolschke, C Berger… - Leukemia, 2020 - nature.com
Currently available data on chimeric antigen receptor (CAR)-T cell therapy has
demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) …

Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials

SZ Usmani, H Nahi, T Plesner, BM Weiss… - The Lancet …, 2020 - thelancet.com
Background Daratumumab showed encouraging efficacy as monotherapy in patients with
heavily pretreated multiple myeloma in the GEN501 and SIRIUS studies. Here we report a …

Beyond clinical trials in patients with multiple myeloma: a critical review of real-world results

L Bertamini, G Bertuglia, S Oliva - Frontiers in Oncology, 2022 - frontiersin.org
The current strategies for the treatment of multiple myeloma (MM) have improved, thanks to
effective drug classes and combination therapies, for both the upfront and relapsed settings …

Multiple myeloma in 2023 ways: from trials to real life

M Fazio, V Del Fabro, NL Parrinello, A Allegra… - Current …, 2023 - mdpi.com
Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse.
Basic research has made giant strides in better characterizing the molecular mechanisms of …

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

S Lovas, G Varga, P Farkas, T Masszi… - International Journal of …, 2019 - Springer
Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of
refractory and relapsed multiple myeloma. We investigated the efficacy and safety of …

[HTML][HTML] Advances in the treatment of extramedullary disease in multiple myeloma

Y Li, Z Sun, X Qu - Translational Oncology, 2022 - Elsevier
Extramedullary disease (EMD) is characterized by plasma cells outside of bone marrow in
multiple myeloma (MM) patients, which results in an adverse prognosis. The cornerstone of …

Central nervous system myeloma and unusual extramedullary localizations: real life practical guidance

V Sammartano, A Cerase, V Venanzi… - Frontiers in …, 2022 - frontiersin.org
Central nervous system localization of multiple myeloma (CNS-MM) accounts for about 1%
of all MM during disease course or even rarer at diagnosis. A difference in the origin, ie …

Monoclonal antibodies in relapsed/refractory myeloma: Updated evidence from clinical trials, real-life studies, and meta-analyses

P Musto, F La Rocca - Expert Review of Hematology, 2020 - Taylor & Francis
Introduction: In the last few years, monoclonal antibodies have rapidly modified the
therapeutic strategies for treating patients with multiple myeloma. Areas covered: In this …

Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy

SS Park, J Min Byun, SS Yoon, K Kim… - British Journal of …, 2021 - Wiley Online Library
Real‐world outcomes of daratumumab monotherapy (DM) for relapsed/refractory multiple
myeloma (RRMM) have remained unclear. We conducted a multicentre retrospective study …